Stockscreener 앱 받기
0.524
4.76%
0.0238
전일 마감가:
$0.5002
열려 있는:
$0.5252
하루 거래량:
101.45K
Relative Volume:
2.39
시가총액:
$20.72M
수익:
-
순이익/손실:
$-24.77M
주가수익비율:
-0.6805
EPS:
-0.77
순현금흐름:
$-17.36M
1주 성능:
-14.94%
1개월 성능:
-25.66%
6개월 성능:
-39.78%
1년 성능:
-47.60%
1일 변동 폭
$0.48
$0.5252
1주일 범위
$0.4632
$0.63
52주 변동 폭
$0.4632
$1.90
Mink Therapeutics Inc Stock (INKT) Company Profile
명칭
Mink Therapeutics Inc
전화
212-994-8250
주소
149 FIFTH AVENUE, NEW YORK
INKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
0.524 | 20.72M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting - GlobeNewswire
Mink Therapeutics stock hits 52-week low at $0.56 amid market challenges - Investing.com Canada
Mink Ventures Commences Diamond Drill Program at Warren Nickel Copper Cobalt Project, Timmins, Ontario - Yahoo Finance
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Business Wire
FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering - BioSpace
Arovella heads toward clinic with CAR-19-iNKT cells - BioWorld Online
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
Geenex Developed Mink Solar Project Approved by Ohio Power Siting Board - Yahoo Finance
Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World
Comparing Fractyl Health (GUTS) and Its Peers - Defense World
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Midwest Energy Emissions Becomes Birchtech Corp. and Announces Equity Incentive Plan AmendmentsOn October 29, 2024, Birchtech Corp. (formerly Midwest Energy Emissions Corp.) filed a Form 8-K with the SEC, detailing recent corporate changes and u - Defense World
Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
Mink Ventures Receives $89,160 in Non-Dilutive Capital With OJEP Grant for Warren Nickel Copper Cobalt Project - Yahoo Finance
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MiNK Therapeutics Sets Q3 2024 Earnings Call: iNKT Cell Therapy Updates Ahead | INKT Stock News - StockTitan
Hedge funds pile into banks, dump green energy post US election, Goldman Sachs says - Yahoo Canada Finance
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 - GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid - The Bakersfield Californian
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
Mink Therapeutics Inc (INKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):